Eli Lilly
Eli Lilly's siRNA Lowers Key Cardiovascular Disease Biomarkers in Phase II Mixed Dyslipidemia Trial
Premium
Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on solbinsiran.
Eli Lilly Drug Cuts Lp(a) in Trial, Raising Its Prospects for Treating Cardiovascular Disease
Premium
Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also improve patients' outcomes.
EMA's CHMP Recommends Against Approval of Eli Lilly's Alzheimer's Drug Kisunla in Europe
The committee determined the clinical benefits of the drug don't outweigh the potentially fatal risk of ARIA.
NICE Still Not Recommending Leqembi, Kisunla for Alzheimer's in Updated Draft Guidance
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
At Some Hospitals, Expert Panels Help Guide Anti-Amyloid Drug Decisions for Alzheimer's Patients
Premium
These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such programs are necessary.